Table 2.
Comparison of hepatocellular carcinoma rate between low and high titers of hepatitis B e antigen in each mutation number group
| Mutation |
HBeAg-positive rate |
HCC rate |
HBeAg < 35 or |
P-value1 | |||
| number |
Total |
HBeAg < 35 |
HBeAg-positive |
HBeAg-negative | HBeAg-negative rate | ||
| % (No./total cases) | % (No./total cases) | HBeAg > 35 | HBeAg < 35 | % (No./total cases) | among HCCs | ||
| % (No./total cases) | % (No./total cases) | % (No./total cases) | |||||
| 0 | 96.6% (28/29) | 7.1% (2/28) | 0% (0/26) | 50% (1/2) | 0% (0/1) | 100% (1/1) | - |
| 1 | 65.2% (15/23) | 13.3% (2/15) | 0% (0/13) | 0% (0/2) | 25.0% (2/8) | 100% (2/2) | - |
| 2-12 | 45.5% (5/11) | 60.0% (3/5) | 0% (0/2) | 33.3% (1/3) | 16.7% (1/6) | 100% (2/2) | - |
| 2-23 | 84.1% (37/44) | 16.2% (6/37) | 6.5% (2/31) | 33.3% (2/ 6) | 28..6% (2/7) | 66.7% (4/6) | 0.0530 |
| 3 | 71.4% (60/84) | 25.0% (15/60) | 10.4% (5/48) | 31.3% (5/16) | 31.4% (11/35) | 76.2% (16/21) | 0.0137 |
| 4 | 48.5% (47/97) | 42.6% (20/47) | 22.2% (6/27) | 45.0% (9/20) | 38.9% (21/54) | 83.3% (30/36) | 0.1047 |
| 5 | 40.0% (26/65) | 46.2% (12/26) | 33.3% (5/15) | 41.7% (5/12) | 28.2% (11/39) | 76.2% (16/21) | 1.0000 |
| 6 | 46.2% (18/39) | 66.7% (12/18) | 57.1% (4/7) | 53.8% (7/13) | 50.0% (11/22) | 81.8% (18/22) | 1.0000 |
| 7 | 47.4% (9/19) | 100% (9/9) | 0% (0/9) | 100% (9/9) | 60.0% (6/10) | 100% (15/15) | - |
| 8 | 12.5% (1/8) | 100% (1/1) | 0% (0/1) | 100% (1/1) | 71.4% (5/7) | 100% (6/6) | - |
1
Fisher’s exact test for count data was carried out to compare the significance of HBeAg status in the prediction of HCC risk between HCC patients with HBeAg > 35 and with HBeAg < 35 or -negative. Low titer HBeAg or HBeAg-negativity is significantly predominant among HCC patients;
2
Only one of two mutations is A1762T or G1764A;
3
Basal core promoter double mutations (A1762T/G1764A). HCC: Hepatocellular carcinoma; HBeAg: Hepatitis B e antigen.